In this analysis were reported by the Abiraterone 154229-19-3 authors as currently in advanced clinical development hlt weight That, if positive Phase III data, probably the largest Direct influence on the management of CRPC in Great Britain Have. Abiraterone acetate, AFL ibercept, bevacizumab custirsen, cabazitaxel, MDV3100, sipuleucel T and zibotentan: hlt were selected therapies. RESULTS In September 2010 98 questionnaires Gene to British-based oncologists distributed and 80 were completed and returned to the BUG for evaluation. The study encompassed a Similar Number of respondents already reported. The authors believe that the sample size in most prostate cancer oncologist Gro Britain and taken to the fi ndings are of clinical relevance and refl ect current practice of managing advanced mCRPC. The first questions the number of remittances and established patients per year will have shown that the reaction of oncologists in Great Britain Had an average of 189 new references for prostate cancer each year, with 24% reporting 200 new references each year. In response, ie chemotherapy oncologists and patients with rapid clinical deterioration and / or short life expectancy. Questions 14 to 16 of the survey were con Us on opinions regarding the likelihood of Changes in clinical practice in the n Chsten 5 years for the treatment of advanced prostate cancer in Gro To assess the impact of Britain and the emerging state of the art therapies were likely to have. Most oncologists believe will reconsider their existing Change rtigen clinical applications in the n Chsten 5 years. When asked about the eight officers currently in advanced clinical development, 71% felt they probably abiraterone acetate in clinical practice was to use the n Chsten 5 years. Similar 31% felt they were very likely to be with, and another 35% thought they k With nnten, MDV3100 in their future practice. The abiraterone acetate and two were described than MDV3100 very much promising And m GE Have a great influence Shows some of the participants in the survey that their thoughts about their experiences with clinical trials of two drugs, as well as reports in the scientific literature that were based. Forty percent of oncologists feel that they are very likely to use cabazitaxel in their clinical practice in the n Chsten 5 years with a further 35% indicating that this is an M Opportunity was had. The reasons for the prior approval of cabazitaxel included the improvement of overall survival, and that efficiency is the efficiency of green cabazitaxel in the second line It as the possibilities for the Behandlungsm Currently observed for patients with advanced mCRPC. However, approval and financing of collaboration Ts were listed as Fludarabine 21679-14-1 potential limiting factors for the future use of cabazitaxel and abiraterone acetate and MDV3100. Views on the future use of the AFL and custirsen ibercept were mixed. Although only 2% of respondents felt very likely that one of these drugs to use in the n Chsten 5 years, felt by 20% and 11% they were unlikely to be the use of these funds, and another 30% and 44 % were undecided. The reasons for this included the clinical experience and the current lack of clinical evidence. Despite his license in the U.S., only 3% of.